CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Clinical Trials Promoting Group (APRIC/CTPG)
Gruppo Oncologico del Lazio (GOL)
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Gruppo Oncologico Italiano di Ricerca Clinica(GOIRC)
Gruppo Oncologico Italia Meridionale
Northwest Oncology Cooperative Group(GONO)
Information provided by (Responsible Party):
National Cancer Institute, Naples
ClinicalTrials.gov Identifier:
NCT00526643
First received: September 6, 2007
Last updated: July 29, 2013
Last verified: July 2013